المساعد الشخصي الرقمي

مشاهدة النسخة كاملة : New Wireless Pacemaker Implanted Without Surgery, Found Safe in Clinical Study


rss
09-11-2015, 09:44 PM
New Wireless Pacemaker Implanted Without Surgery, Found Safe in Clinical Study
http://www.medgadget.com/wp-content/uploads/2015/09/leadless-pacemaker.jpg A*study, published in New England Journal of Medicine, describes the use of a new pacemaker that can be implanted into the heart without the necessity for surgery*to test its safety and efficacy in fragile patients who require permanent pacing for **rmal functioning of the heart.

http://www.medgadget.com/wp-content/uploads/2015/09/leadless-pacemaker-side.jpgThe device, the Na**stim (http://www.medgadget.com/2014/05/worlds-smallest-endocardial-pacemaker-getting-implanted-in-initial-set-of-patients.html)from St. Jude Medical, which only measures 6mm in diameter and 42mm in length, can be implanted into either*side of the heart using a catheter inserted via*the leg arteries, similar to how stents are currently placed. Moreover, unlike traditional pacemakers, the device does **t need an external generator or wires to function. Instead, a small battery with an estimated lifetime of 15 years is built into the device.

“This is a**ther landmark in the development of pacemakers” said*Dr. Christopher Granger of the American Heart Association (http://medicalxpress.com/news/2015-08-tiny-wireless-pacemaker-surgery-free-option.html), who was **t part of the new study. However, he cautions*that more testing needs to be done before the device can function well in patients.*The pacemaker has already been approved for use in Europe and is to be submitted to the US Food and Drug Administration (FDA) soon.

From the results section of the study abstract:

<blockquote>
The leadless pacemaker was successfully implanted in 504 of the 526 patients in the total cohort (95.8%). The intention-to-treat primary efficacy end point was met in 270 of the 300 patients in the primary cohort (90.0%; 95% confidence interval [CI], 86.0 to 93.2, P=0.007), and the primary safety end point was met in 280 of the 300 patients (93.3%; 95% CI, 89.9 to 95.9; P